High-dose intravenous pamidronate for metastatic bone pain

British Journal of Cancer

Volumn 70, Issue 3, 1994, Pages 554-558

  Purohit, O P ^a   Anthony, C ^a   Radstone, C R ^a   Owen, J ^a   Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; PAMIDRONIC ACID;

ARTICLE; BONE METASTASIS; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG USE; FEMALE; FEVER; HUMAN; HYPOCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; JOINT MOBILITY; MALE; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

BONE AND BONES; BONE NEOPLASMS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN; HYPOCALCEMIA; INFUSIONS, INTRAVENOUS; MALE; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE;

EID: 0028060450     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1994.344     Document Type: Article

References (24)

1. ADAMI, S. & MIAN, M. (1989). Clodronate therapy of metastatic bone disease in patients with prostatic cancer. In Bisphosphonates and Tumour Osteolysis, Brunner, K.W., Fleisch, H. & Senn, H.-J. (eds) pp. 67-72. Springer Heidelberg.
2. BODY, J.J., POT, M., BORKWSKI, A., SCUUER, J.P. & KLASTERSKY, J. (1987). Dose response study of aminohydroxypropyhdene bisphosphonate in tumor-associated hypercalcemia. Am. J. Med., 82, 957.
3. BURCKHARDT, P., THIEBAUD, D., PEREY, L. & VON FUEDNER, V. (1989). Treatment of tumour induced osteolysis by APD. Rec. Res. Cancer Res., 116, 54.
4. CLARKE, N.W., HOLBROOK, I.B., MCCLURE, J. & GEORGE, N.J. (1991). Osteoclast inhibition by pamidronate in metastatic prostate cancer a preliminary study. Br. J. Cancer, 63, 420–423.
5. COLEMAN, R.E. & RUBENS, R.D. (1987). The clinical course of bone metastases from breast cancer. Br. J. Cancer, 55, 61.
6. COLEMAN, R.E. & PUROHIT, O.P. (1993). Osteoclast inhibition for the treatment of bone metastases. Cancer Treat. Rev., 19, 79.
7. COLEMAN, R.E. (1991). Assessment of response to treatment In Borte Metastases - Diagnosis and Treatment, Rubens, R.D. & Fogieman, I. (eds) p. 99. Springer London.
8. COLEMAN, R.E., WOLL, PJ., MILES, M., SCRIVENER, W. & RUBENS, R.-D. (1988). 3-Amino-1, 1 hydroxypropylidene bisphosphonate (APD) for the treatment of hone metastases from breast cancer. Br. J. Cancer, 58, 621.
9. DALEY-YATES, P.T., DODWELL, D.J., PONGCHAIDECHA, M., COLEMAN, R.E. & HOWELL, A. (1991). The clearance and bioavailabihty of pamidronate in patients with breast cancer and bone metastases. Calcif. Tissue Int., 49, 433.
10. DE HAES, J.C.M., KNIPPENBERG, F.C.E. & NEUT, J.P. (1990). Measuring psychological and physical distress in cancer patients: application of the Rotterdam Symptom Checklist Br. J. Cancer, 62, 1034.
11. ERNST, D.S., MACDONALD, N., PATERSON, A.H.G., JENSON, J., BRASHER, P. & BRUERA, E. (1992). A double Wind, crossover trial of intravenous dodronate in metastatic bone pain. J. Pain Symptom Management, 7, 4.
12. FAIRBANK, J.C.T., COUPER, J., DAVIES, J.B. & O’BRIEN, J.P. (1980). The Oswestry low back questionnaire. Physiotherapy, 66, 271.
13. MI ION, A. & McTAVTSH, D. (1991). Pamidronate - a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs, 41, 289.
14. GALASKO, C.B.E. (1976). Mechanisms of bone destruction in the development of skeletal metastases. Nature, 263, 507.
15. GRABELSKY, S., UPTON, A, HARVEY, H., GLOVER, D., BROWNING, S., DILLMAN, R., FRAM, R.J., GEORGE, S., KELLER, A, MILLER, A. & SEAMAN, J. (1991). Pamidronate disodium (APD) - a dose-seeking study in patients with breast cancer. Proc. Am. Soc. Clin. Oncol., 16, 42 (abstract 41).
16. HACKING, A., GUDGEON, C.A., McNAUGHTON, D. & DENT, D.M. (1991). Disodium pamidronate (Aredia) as single infusion monotherapy in the treatment of bone metastases from breast cancer. In Osteoclast Inhibition in the Management of Malignancy Related Bone Disorders, Bijvoet, O.L.M. A Lipton, A. (eds) pp. 45-53. Hogrefe A Huber Bern.
17. MORTON, A.R., CANTRILL, J.A., PILLAI, G.V., MCMAHON, A., ANDERSON, D.C. & HOWELL, A. (1988). Sclerosis of lytic bone métastasés after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast cancer. Br. Med. J., 297, 772.
18. PATERSON, A.H.G., POWLES, T.J., KANIS, J.A., MCCLOSKEY, E., HANSON, J. & ASHLEY, S. (1993). Double blind controlled trial of clodronate in patients with bone métastasés from breast cancer. J. Clin. Oncol., 11, 59.
19. PUROHIT, O.P., DICKSON, I. & COLEMAN, R.E. (1994). Effect of a single high dose treatment with pamidronate on markers of bone resorption in patients with bone métastasés. Br. J. Cancer, 69 (Suppl. XXI), 45.
20. RALSTON, S.H., GARDNER, M.D., DRYBURGH, F.J., JENKINS, A.S., COWAN, R.A. & BOYLE, I.T. (1985). Comparison of amino- hydroxypropylidene diphosphonate, mithramycin, and corti- costeroids/caicitonin in treatment of cancer-associated hypercal- caemia. Lancet, i, 907.
21. TYRRELL, CJ., BRUNING, P.F., MAY-LEVIN, F., ROSE, C. & FORD, J.M. (1993). Non comparative multi-centre open trial in patients with breast cancer and bone metastases to investigate the effect of apd (pamidronate) on bone healing, morbidity and bone metabolism. Breast, 2, 202.
22. TYRELL, CJ., MADSEN, E.L., COLLINSON, M., FORD, J.M. & COLEMAN, T. (1993). A study of renal function of four infusions of pamidronate 90 mg given over 60 min one week apart. Eur. J. Cancer, 29A (Suppl. 6), 282.
23. VAN HOLTEN-VERZANTVOORT, A.T., KROON, H.M., BUVOET, CLETON, F.J., BEEX, L.V.A.M., BLUHAM, G., HERMANS, J., NEUT, J.P., PAPAPOULOS, S.E., SLEEBOOM, H.P., VERMEY, P. & ZWINDERMAN, A.H. (1993). Palliative bone treatment in patients with bone metastases from breast cancer. J. Clin. Oncol., 11, 491–498.
24. WHO (1979). Handbook for Reporting Results of Treatment. WHO: Geneva.